Absynth Biologics Ltd. aims to harness patients’ own immune systems in the fight to prevent and treat bacterial infections; its platform identifies proteins on the cell membranes of bacteria that are essential for their survival, and are highly conserved. Combinations of these proteins, with additive or synergistic potential, are then used to create vaccines and antibodies that may inhibit bacterial activity, as well as engage the immune system to attack and eliminate the infection.

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Each month, Start-Up presents a comprehensive review of young, private life science companies that have recieved venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.